<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Spinal Cord Lamina I Pain Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Spinal Cord Lamina I Pain Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
Spinal cord lamina I constitutes the most superficial layer of the dorsal horn and serves as the primary gateway for nociceptive information transmission to the brain. First described by Rexed in 1952, lamina I has since been recognized as a critical node in pain processing, containing heterogeneous neuronal populations that encode pain intensity, quality, and affective components. These neurons are particularly relevant to neurodegenerative disease research because they represent the first central synapse in the pain pathway and undergo significant plastic changes in chronic pain states associated with conditions such as Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. [@todd2010]
Lamina I contains approximately 10-15% of neurons in the dorsal horn but receives the majority of nociceptive input from primary afferent fibers. The complexity of lamina I neuronal populations reflects the diverse information they process—from acute pain detection to chronic pain states that outlast initial tissue damage. Understanding the organization and function of these neurons provides essential insight into both normal pain processing and the dysregulated states that characterize neuropathic and inflammatory pain in neurodegenerative contexts.
Lamina I projection neurons constitute the major output pathway from the spinal dorsal horn to supraspinal structures. These neurons can be classified into several distinct populations based on their axonal projections and neurochemical properties. The most extensively studied are spinothalamic tract (STT) cells, which project to the ventral posterolateral and ventral posteromedial nuclei of the thalamus. These neurons are critical for the sensory-discriminative component of pain, providing information about pain location, intensity, and temporal characteristics to primary somatosensory cortex. [@begbie2002]
A second major population projects to the parabrachial nucleus (PBN), a brainstem structure involved in autonomic and affective responses to pain. Spinoparabrachial neurons originate primarily from the lateral margin of lamina I and express the neurokinin 1 receptor (NK1R), making them susceptible to targeting by substance P. These neurons are essential for the affective-emotional component of pain and project to the amygdala, bed nucleus of the stria terminalis, and hypothalamus—structures implicated in fear, anxiety, and stress responses that are frequently dysregulated in neurodegenerative conditions. [@zhao2017]
A third population projects to the periaqueductal gray (PAG), the central hub of endogenous pain modulation. These neurons engage descending modulatory pathways that can either facilitate or inhibit nociceptive transmission at the spinal level. The PAG receives input from lamina I and, in turn, projects to the rostral ventromedial medulla (RVM), which contains serotonergic and noradrenergic neurons that modulate dorsal horn neuron excitability. This descending circuitry is profoundly altered in chronic pain states and represents a therapeutic target for opioid and antidepressant-based analgesics.
Based on dendritic architecture, lamina I neurons have been classified into several morphological types. Fusiform or bipolar neurons possess elongated dendritic trees oriented parallel to the dorsal surface and represent the majority of projection neurons. These cells receive input from both superficial and deeper dorsal horn layers, integrating information across multiple segments. [@todd2010]
Pyramidal neurons, with their characteristic triangular soma and vertically oriented dendritic field, constitute a smaller population that extends dendrites into lamina II. These neurons appear to correspond to the recently identified "low-threshold" mechanoreceptive population that responds to innocuous touch but becomes sensitized in chronic pain states.
Stellate or multipolar neurons represent the most diverse morphological group, with dendritic fields extending in all directions. Many of these cells are local circuit neurons that modulate the activity of projection neurons and other interneurons, providing the substrate for complex processing within lamina I itself.
Lamina I neurons express a remarkable diversity of neurochemical markers. The majority of projection neurons express the neuronal nitric oxide synthase (nNOS), while a subset contains somatostatin or dynorphin. The NK1R-expressing population, which receives direct input from substance P-containing primary afferents, has been particularly implicated in chronic pain states and represents a potential therapeutic target. [@henwood2022]
GABAergic and glycinergic interneurons constitute approximately 30-40% of lamina I neurons and provide inhibitory control over projection neuron excitability. These neurons express markers including parvalbumin, calretinin, and neuropeptide Y, allowing molecular targeting for analgesia. The balance between excitation and inhibition in lamina I is critical—loss of inhibitory control contributes to central sensitization and chronic pain.
Lamina I neurons receive synaptic input from two major classes of primary afferent fibers. Aδ-fibers, with their medium conduction velocities (5-30 m/s), mediate fast, sharp pain and express the heat-sensitive ion channel TRPV1 as well as mechanosensitive Piezo2 channels. C-fibers, the slowest-conducting unmyelinated fibers (<1 m/s), mediate dull, aching pain and are characterized by their sensitivity to capsaicin (TRPV1), mustard oil (TRPA1), and ATP (P2X3).
The transient receptor potential (TRP) family of ion channels has emerged as critical transducers of noxious stimuli. TRPV1 responds to heat (>43°C), capsaicin, and acidic pH, making it essential for thermal and chemical nociception. TRPA1 detects mustard oil, garlic, and environmental irritants, while TRPM8 responds to cold temperatures and cooling agents. These channels depolarize nociceptive terminals, triggering glutamate and neuropeptide release onto lamina I neurons. [@grafe2020]
Ionotropic glutamate receptors, particularly AMPA and NMDA receptors, mediate fast excitatory transmission in lamina I. NMDA receptors require prior depolarization for full activation (voltage-dependent magnesium block), making them critical for activity-dependent plasticity. Repeated C-fiber activation removes the magnesium block, allowing calcium influx that triggers intracellular cascades leading to central sensitization—a state of enhanced neuronal excitability that underlies chronic pain.
Nociceptive transmission in lamina I involves complex intracellular signaling cascades. Activation of NK1R by substance P activates phospholipase C (PLC), leading to protein kinase C (PKC) activation and subsequent phosphorylation of NMDA and AMPA receptors, enhancing their conductance. PKC also phosphorylates TRPV1, reducing its thermal threshold and contributing to heat hyperalgesia.
The mitogen-activated protein kinase (MAPK) family, including ERK, p38, and JNK, are activated in lamina I neurons following noxious stimulation. ERK phosphorylation in dorsal horn neurons correlates with pain behavior and is maintained in chronic pain states. p38 MAPK is activated in microglia and astrocytes following nerve injury, contributing to neuroinflammation and pain hypersensitivity through cytokine release. [@henwood2022]
Cyclic AMP response element-binding protein (CREB) phosphorylation links nociceptive input to gene expression changes in lamina I neurons. CREB-regulated genes include dynorphin, which acts as an endogenous opioid, and brain-derived neurotrophic factor (BDNF), which potentiates NMDA receptor function and contributes to central sensitization. These molecular changes persist long after the initial injury, explaining the transition from acute to chronic pain.
The spinothalamic tract originates from lamina I neurons that cross in the anterior commissure and ascend in the anterolateral funiculus. STT neurons terminate in the ventral posterolateral (VPL) and ventral posteromedial (VPM) nuclei of the thalamus, with additional projections to the central lateral (CL) and intralaminar nuclei. The VPL/VPL complex projects to primary somatosensory cortex (S1), providing the sensory-discriminative dimension of pain—the "where" and "how much" of pain experience.
Functional imaging studies in humans have revealed that S1 activation correlates with pain intensity ratings, while lesions to this area produce sensory deficits without eliminating the affective component of pain. This confirms the hierarchical organization of pain processing, with lamina I-STT-VPL-S1 forming the core of the sensory pathway that is disrupted in various neurodegenerative conditions.
The central lateral nucleus and intralaminar nuclei project to anterior cingulate cortex (ACC) and prefrontal areas, providing the affective-motivational component of pain. These nuclei also project to basal ganglia and limbic structures, linking pain to emotional processing and motor planning. Importantly, these pathways are implicated in the pain avoidance behaviors that are compromised in Parkinson's disease and other movement disorders.
The spinoparabrachial pathway originates from the lateral margin of lamina I and projects to the lateral division of the parabrachial nucleus. From PBN, projections extend to the nucleus of the solitary tract (NTS), ventrolateral medulla, and hypothalamic nuclei. Critically, PBN sends dense projections to the central nucleus of the amygdala, establishing a direct link between spinal nociceptive input and emotional processing. [@uchida2020]
This pathway is essential for the affective component of pain—the "how bad it feels." Activation of this pathway produces autonomic responses (tachycardia, hypertension, pupillary dilation), fear and anxiety behaviors, and glucocorticoid release. The amygdala, a key target of PBN projections, shows altered structure and function in chronic pain states and in neurodegenerative diseases including Alzheimer's and Parkinson's disease.
The periaqueductal gray (PAG) receives input from lamina I neurons and integrates it with forebrain signals to generate descending modulatory commands. PAG projects to the rostral ventromedial medulla (RVM), which contains three classes of neurons: "on-cells" that facilitate pain, "off-cells" that inhibit pain, and "neutral cells" that are unrelated to nociception. RVM neurons project back to the dorsal horn via the dorsolateral funiculus, terminating in lamina I and II.
Serotonin (5-HT) and norepinephrine (NE) released from RVM terminals activate 5-HT1A, 5-HT2, α2-adrenergic receptors on dorsal horn neurons, producing analgesia through presynaptic inhibition of primary afferent terminals and postsynaptic inhibition of projection neurons. This endogenous opioid-independent mechanism underlies the analgesic effects of tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors (SNRIs) used for neuropathic pain.
In chronic pain states, descending facilitation predominates over inhibition. RVM "on-cell" activity increases, and 5-HT released from RVM terminals acts on 5-HT3 receptors on dorsal horn neurons to enhance, rather than inhibit, nociceptive transmission. This maladaptive plasticity represents a therapeutic target—5-HT3 antagonists such as ondansetron have shown efficacy in some chronic pain conditions.
Pain is a common non-motor symptom of Parkinson's disease (PD), affecting up to 60% of patients. While often attributed to musculoskeletal causes, emerging evidence indicates that central pain processing mechanisms are fundamentally altered. Studies using quantitative sensory testing have revealed elevated pain thresholds, impaired pain discrimination, and abnormal temporal summation in PD patients, suggesting involvement of spinal and supraspinal pain pathways. [@cocozza2020]
Lamina I neurons may contribute to PD-related pain through several mechanisms. First, dopaminergic signaling modulates dorsal horn neuronal excitability—loss of dopaminergic inhibition could enhance pain transmission. Second, α-synuclein pathology affects spinal cord interneurons, potentially disrupting the balance of excitation and inhibition in lamina I. Third, PD-related neuroinflammation could sensitize dorsal horn neurons through cytokine and chemokine signaling.
Functional imaging studies have revealed altered activation patterns in PD patients during pain stimulation, with reduced PAG responses suggesting impaired descending inhibition. This finding correlates with clinical observations that PD patients show poor response to opioid analgesics, reflecting the compromised endogenous pain modulation systems that depend on dopaminergic signaling.
Amyotrophic lateral sclerosis (ALS) primarily affects motor neurons, but sensory abnormalities are increasingly recognized. Patients report neuropathic pain, often with burning or tingling quality, and quantitative sensory testing reveals elevated thermal and mechanical detection thresholds. While motor neuron degeneration is the hallmark of ALS, spinal interneurons including those in lamina I are also affected.
Lamina I projection neurons express SOD1, the protein mutated in familial ALS, and show early pathology in mouse models of the disease. These neurons undergo degeneration before motor neuron loss becomes apparent, suggesting they may serve as early biomarkers. The involvement of lamina I neurons in ALS may explain the sensory symptoms that accompany motor dysfunction and may contribute to the pain that affects up to 70% of ALS patients.
Multiple sclerosis (MS) commonly involves pain, both as a direct symptom of demyelination in pain pathways and as a secondary consequence of spasticity and immobility. Lamina I neurons may be directly affected by demyelination of dorsal horn circuits, disrupting the precise temporal coding required for accurate pain transmission. Additionally, MS-related neuroinflammation could sensitize these neurons through cytokine-mediated mechanisms.
While pain perception deficits are recognized in Alzheimer's disease (AD), the underlying mechanisms remain poorly understood. Patients show reduced sensitivity to experimental pain stimuli and may fail to report pain that would normally prompt medical attention. This analgesia could reflect amyloid pathology in pain-processing pathways, including lamina I and its supraspinal targets.
Studies in AD mouse models have revealed amyloid deposition in dorsal horn neurons, including those in lamina I. Amyloid-β accumulation could disrupt synaptic function and alter the balance of excitation and inhibition in pain circuits. Alternatively, tau pathology in spinothalamic tract neurons could impair pain signal transmission to cortical areas responsible for pain perception.
The high density of voltage-gated sodium channels in lamina I neurons makes them attractive analgesic targets. Nav1.7 and Nav1.8 are preferentially expressed in nociceptive neurons and have been validated as analgesic targets through genetic studies—loss-of-function mutations produce congenital insensitivity to pain, while gain-of-function mutations cause painful disorders. Several Nav1.7 and Nav1.8 blockers are in clinical development for chronic pain. [@grafe2020]
TRPV1 antagonists have been extensively investigated for pain relief but have faced challenges due to hyperthermia and impaired temperature regulation. Selective targeting of TRPV1 expressed in lamina I neurons, rather than globally, could provide analgesia while minimizing side effects. Alternatively, TRPV1 agonists (capsaicin, resiniferatoxin) can produce extended analgesia through defunctionalization of nociceptive terminals.
P2X3 receptors, activated by ATP released from damaged cells, represent another target for pain intervention. P2X3-expressing lamina I neurons are sensitized in chronic pain states, and P2X3 antagonists have shown efficacy in preclinical models. The A-967079 compound, a selective P2X3 antagonist, completed Phase 2 clinical trials for chronic cough and shows promise for pain indications.
Opioid receptors (μ, δ, κ) are expressed in lamina I neurons and their presynaptic terminals. μ-opioid receptor agonists remain the most effective analgesics but carry risks of respiratory depression, dependence, and tolerance. Novel strategies include targeting biased agonists that activate G-protein signaling without β-arrestin recruitment, potentially retaining analgesia with reduced side effects.
NK1R antagonists were extensively investigated for pain and depression but failed in clinical trials, likely because substance P signaling is redundant with other nociceptive pathways. However, selective targeting of NK1R-expressing lamina I projection neurons, rather than global receptor blockade, may provide benefit with fewer CNS side effects.
Optogenetic manipulation of lamina I neurons has emerged as a powerful research tool and holds therapeutic potential. Expressing channelrhodopsin in NK1R-expressing neurons and activating them with blue light produces analgesia in mouse models, while halorhodopsin-mediated inhibition reduces pain behaviors. While clinical application requires non-invasive delivery methods, these studies demonstrate the therapeutic potential of targeting specific lamina I populations. [@mantle2022]
Chemogenetic approaches using designer receptors (DREADDs) allow targeted manipulation of neuronal populations through systemic administration of clozapine-N-oxide (CNO). Activating excitatory DREADDs in lamina I projection neurons reproduces pain behaviors, while inhibiting them produces analgesia. This approach could be refined by targeting DREADD expression using promoter sequences specific to lamina I populations.
Gene therapy approaches aim to deliver analgesic transgenes to lamina I neurons. Viral vectors encoding channel-blocking peptides, anti-inflammatory cytokines, or inhibitory opsins could provide long-lasting analgesia with single administration. Preclinical studies have shown efficacy of AAV-delivered shRNA targeting Nav1.7 and of GAD67 overexpression to enhance GABAergic inhibition.
Spinal cord lamina I neurons represent the critical first central synapse in pain processing, integrating input from primary nociceptive afferents and transmitting pain signals to brain regions that subserve sensory, affective, and autonomic dimensions of the pain experience. The cellular heterogeneity of lamina I—projection neurons targeting diverse brain areas, excitatory and inhibitory interneurons, neurons with distinct morphological and neurochemical properties—provides the substrate for complex processing that goes beyond simple relay.
The role of lamina I in neurodegenerative diseases is increasingly recognized, with implications for both understanding disease pathophysiology and developing novel therapies. In Parkinson's disease, altered lamina I function contributes to central pain processing abnormalities. In ALS, early involvement of lamina I neurons may explain sensory symptoms. In MS, demyelination of dorsal horn circuits disrupts pain transmission. In Alzheimer's disease, amyloid and tau pathology may impair pain perception.
Therapeutic targeting of lamina I neurons requires precision—general inhibition produces analgesia but also disrupts protective sensations and autonomic functions. The emerging understanding of specific neuronal populations within lamina I, combined with molecular tools for selective manipulation, creates opportunities for developing analgesics with improved efficacy and safety profiles. As the population of patients with neurodegenerative diseases grows, understanding and treating pain in these conditions becomes an increasingly important clinical priority.